Literature DB >> 7911490

Distinct effects of human herpesvirus 6 and human herpesvirus 7 on surface molecule expression and function of CD4+ T cells.

M Furukawa1, M Yasukawa, Y Yakushijin, S Fujita.   

Abstract

This study was undertaken to investigate the effects of newly isolated T lymphotropic viruses, human herpesvirus (HHV)-6 and HHV-7, on CD4+ T cells. We first examined changes in surface molecule expression on CD4+ T cells after infection with HHV-6 or HHV-7 by flow cytometry. Among surface molecules examined, CD3 expression appeared to decline markedly after infection with HHV-6 variant A (strain U1102) but the decreased level of CD3 expression after infection with HHV-6 variant B (strain Z29) was slight. Impairment of surface CD3 expression on HHV-6 variant A-infected cells was also demonstrated by measuring intracellular free Ca2+ concentration in response to anti-CD3 mAb. In contrast, HHV-7 infection induced a marked loss of surface CD4 expression, but the decline of CD3 expression was slight. Cytotoxic activity of virus-specific CD4+ CTL clones decreased after infection with both HHV-6 variant A or HHV-7 but the degree of reduction of cytotoxicity by HHV-6 variant B was not significant. Addition of lectin restored the cytotoxicity of HHV-7-infected CTL but not that of HHV-6 variant A-infected CTL. Northern blot analysis and immunoprecipitation showed that infection with HHV-6 and HHV-7 did not affect the transcription and protein synthesis of CD3 and CD4. These findings suggest that both HHV-6 and HHV-7 may directly cause T cell immunodeficiency but that the mechanisms of CD4+ T cell dysfunction mediated by HHV-6 and HHV-7 are different.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911490

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  The U24 protein from human herpesvirus 6 and 7 affects endocytic recycling.

Authors:  Brian M Sullivan; Laurent Coscoy
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

3.  CXC-chemokine receptor 4 is not a coreceptor for human herpesvirus 7 entry into CD4(+) T cells.

Authors:  Y Zhang; S Hatse; E De Clercq; D Schols
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Induction of T-cell apoptosis by human herpesvirus 6.

Authors:  Y Inoue; M Yasukawa; S Fujita
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Human herpesvirus 7 infection of lymphoid and myeloid cell lines transduced with an adenovirus vector containing the CD4 gene.

Authors:  M Yasukawa; Y Inoue; H Ohminami; E Sada; K Miyake; T Tohyama; T Shimada; S Fujita
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

Review 6.  Immune response to HHV-6 and implications for immunotherapy.

Authors:  Aniuska Becerra; Laura Gibson; Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  Curr Opin Virol       Date:  2014-10-27       Impact factor: 7.090

7.  Productive infection of primary macrophages with human herpesvirus 7.

Authors:  Y Zhang; L de Bolle; S Aquaro; A van Lommel; E De Clercq; D Schols
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Phenotypic and functional alterations of dendritic cells induced by human herpesvirus 6 infection.

Authors:  Miki Kakimoto; Atsuhiko Hasegawa; Shigeru Fujita; Masaki Yasukawa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Human herpesvirus 6 infection impairs Toll-like receptor signaling.

Authors:  Yuichi Murakami; Kazushi Tanimoto; Hiroshi Fujiwara; Jun An; Koichiro Suemori; Toshiki Ochi; Hitoshi Hasegawa; Masaki Yasukawa
Journal:  Virol J       Date:  2010-05-10       Impact factor: 4.099

Review 10.  Lymphoproliferative Syndromes Associated with Human Herpesvirus-6A and Human Herpesvirus-6B.

Authors:  Eva Eliassen; Gerhard Krueger; Mario Luppi; Dharam Ablashi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-05-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.